Nanocis (Rhenium Sulfide)

Rhenium sulfide is thought to influence cellular redox pathways and metal‑dependent enzymes, which may affect cell proliferation and survival. The precise mechanism is still under investigation and may vary with the disease model.

The dosage of Nanocis is determined by the prescribing clinician based on the specific study protocol or therapeutic context. No standardized dosing regimen is publicly available.

Safety data for Rhenium sulfide in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk, and to discuss options with a healthcare professional.

To request Nanocis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Nanocis (Rhenium sulfide) belongs to a class of metal‑based compounds under investigation for similar therapeutic areas. Compared with other agents, its unique rhenium core may offer distinct redox‑modulating properties, but head‑to‑head efficacy and safety data are not yet available.

Nanocis should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability.

Nanocis can be given orally as a liquid or tablet formulation, or by subcutaneous injection, depending on the clinical protocol. Administration routes and techniques are defined by the treating physician.

The most serious potential risks include hypersensitivity reactions, organ toxicity that has not been fully characterized, and rare hematologic or neurologic adverse events. Patients should be monitored closely for any unexpected symptoms.

Individuals with known hypersensitivity to metal sulfides, those with severe renal or hepatic impairment, pregnant or breastfeeding women (unless clearly indicated), and patients receiving conflicting investigational agents should avoid Nanocis unless a specialist determines it is appropriate.